U.S. Markets closed

Amryt Pharma plc (AMYT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.18-0.15 (-1.32%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.33
Open11.18
Bid11.18 x 1100
Ask14.15 x 900
Day's Range11.12 - 11.44
52 Week Range10.06 - 15.44
Volume32,017
Avg. Volume79,766
Market Cap401.105M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • 10 Best Stocks to Buy According to Highbridge Capital
    Insider Monkey

    10 Best Stocks to Buy According to Highbridge Capital

    In this article we will take a look at the 10 best stocks to buy according to billionaire Glenn Russell Dubin’s Highbridge Capital Management. You can skip our detailed analysis of Dubin’s history, investment philosophy, and hedge fund performance, and go directly to the 5 Best Stocks to Buy According to Billionaire Glenn Russell Dubin’s […]

  • Amryt (AMYT) NDA for Skin Disorder Drug Gets Priority Review
    Zacks

    Amryt (AMYT) NDA for Skin Disorder Drug Gets Priority Review

    Amryt (AMYT) is seeking approval for Oleogel-S10 as a potential treatment for patients with rare and distressing genetic skin disorder, epidermolysis bullosa.

  • Amryt Pharma's Oleogel-S10 Application Gets FDA Priority Review Tag for Skin Blistering Disorder
    Benzinga

    Amryt Pharma's Oleogel-S10 Application Gets FDA Priority Review Tag for Skin Blistering Disorder

    The FDA has granted priority review status to Amryt Pharma's (NASDAQ: AMYT) marketing application seeking approval for Oleogel-S10 to treat Epidermolysis Bullosa (EB). Oleogel-S10 is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic EB, a rare genetic skin disorder characterized by blistering lesions on the skin and mucous membranes. In general, the FDA's Priority Review designation accelerates the review time from ten months to a goal of six months from the dat